脓毒症发病机制及β受体阻滞剂用于早期脓毒症治疗的研究进展

Research progress of sepsis pathogenesis and application of β-blockers in treatment of early sepsis

脓毒症由感染导致,并引发全身炎症反应,重症患者可合并多器官功能障碍.虽然全世界医学界同仁多次发起拯救脓毒症的倡议,并反复制定和更新脓毒症集束化治疗方案,但脓毒症病死率仍居高不下.脓毒症引起全身炎症反应失控.大多数与脓毒症相关的免疫细胞表面表达β肾上腺素能受体,故而在脓毒症早期β受体起到了至关重要的作用.β受体阻滞剂作为心血管系统疾病的传统用药,近年来应用于交感兴奋性疾病并显示出可以降低病死率、改善预后的效果.故而将β受体阻滞剂用于早期脓毒症患者,可下调其炎症反应程度,从而达到保护器官的作用.

Sepsis is caused by infection,leading to systemic inflammatory response,and severe patients can be complicated with multiple organ dysfunctions.Although colleagues in medical community all over the world have launched multiple times of initiatives to rescue patients with sepsis,and repeatedly formulated and updated cluster treatment guidelines of sepsis,the mortality of sepsis remains high without decreasing trend.Sepsis gives rise to out of control of systemic inflammatory response.Most of immune cells associated with sepsis expressing β-adrenergic receptors on cell surfaces,so β receptors play a crucial role in early stage of sepsis.β-blockers as traditional drug for treatment of cardiovascular systematic diseases,have been used in sympathetic nerve excitability disease in recent years,and have shown effect of reducing mortality and improving prognosis.Therefore β-blockers used in patients with early sepsis may down-regulate the degree of inflammatory response,so as reaching to protect functions of various organs.